Search clinical trials for: Kras mutation

Total 4444 results

Quanta Therapeutics

Not yet recruiting

QTX3046 in Patients With KRAS G12D Mutations

Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
M.D. Anderson Cancer Center

Not yet recruiting

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Metastatic Colorectal Cancer | KRAS G12C Mutations

United States
Tyligand Bioscience (Shanghai) Limited

Recruiting

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Malignant Neoplasm

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Memorial Sloan Kettering Cancer Center
Amgen

Recruiting

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Nested Therapeutics, Inc

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

Australia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Non Small Cell Lung Cancer

China
Ikena Oncology

Recruiting

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Colorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene Mutation

United States
National Cancer Institute (NCI)

Recruiting

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Gastrointestinal Cancer | Genitourinary Cancer | Metastatic Solid Cancers

United States
Amgen

Not yet recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

Metastatic Colorectal Cancer
Sichuan Huiyu Pharmaceutical Co., Ltd

Recruiting

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

Efficacy | Tolerability | Safety

China
Frontier Medicines Corporation

Recruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)

Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C Mutations

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Solid Tumor | KRAS Mutation-Related Tumors

China
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
Quanta Therapeutics

Recruiting

QTX3034 in Patients With KRAS G12D Mutation

Solid Tumors

United States
Neogene Therapeutics, Inc.

Recruiting

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Endometrial Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Colorectal Carcinoma | Solid Tumor, Adult | KRAS G12D

United States
Incyte Corporation

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Solid Tumors

United States, France, Italy, Australia, Spain, Canada, Belgium
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
Revolution Medicines, Inc.

Recruiting

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC)

United States, Puerto Rico
BeBetter Med Inc
Xiangya Hospital of Central South University

Recruiting

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Advanced or Metastatic Solid Tumor | KRAS G12C Mutation

China
Cardiff Oncology
Pfizer

Recruiting

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Metastatic Colorectal Cancer | CRC | KRAS/NRAS Mutation

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Advanced Solid Tumors

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Recruiting

A Study of YL-17231 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
Fred Hutchinson Cancer Center
Affini-T Therapeutics, Inc.

Recruiting

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Metastatic Colorectal Adenocarcinoma | Stage IV Lung Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8

United States
Incyte Corporation
Mirati Therapeutics Inc.

Recruiting

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Advanced Solid Tumors

United States, Canada, Spain, United Kingdom, Italy
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Advanced Solid Tumor

China
Murdoch Childrens Research Institute
Royal Children's Hospital; Peter MacCallum Cancer Centre, Australia

Not yet recruiting

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)

Arteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditions

Australia
AstraZeneca

Recruiting

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA (ERA)

Breast Cancer

Russian Federation
Genfit

Recruiting

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma

Cholangiocarcinoma

United States, Puerto Rico
Mirati Therapeutics Inc.

Recruiting

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Lung

Korea, Republic of, United States, Turkey, France, Taiwan, Spain
NYU Langone Health

Recruiting

Ladarixin With Sotorasib in Advanced NSCLC

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170)

Non-Small Cell Lung Cancer

Korea, Republic of, Canada, United States, Australia, Brazil, China, United Kingdom, Israel, Belgium, Netherlands, Argentina, Spain, Taiwan, Italy, Poland, Turkey, Sweden, Switzerland
Black Diamond Therapeutics, Inc.

Recruiting

A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Melanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditions

United States
GenEros Biopharma Hangzhou Ltd

Recruiting

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Advanced Solid Tumors

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Advance Non-small Cell Lung Cancer

Spain, Italy, Greece
Mirati Therapeutics Inc.

Recruiting

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Pancreatic Adenocarcinoma | Solid Tumor | Advanced Solid Tumor | Non-small Cell Lung Cancer | Colo-rectal Cancer

United States
Verastem, Inc.

Recruiting

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205)

Metastatic Cancer | Pancreas Cancer | Neoplasms Pancreatic | KRAS Activating Mutation | Malignant Neoplasm of Pancreas

United States
Georgetown University
Immune System Key Ltd

Recruiting

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Solid Tumor | KRAS Mutation-Related Tumors

United States
Mandana Kamgar, MD

Recruiting

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Pancreatic Ductal Adenocarcinoma

United States
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
Mirati Therapeutics Inc.

Recruiting

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (202200050434)

Metastatic Lung Cancer | Advanced NSCLC

United States, Spain, Greece, Hungary, France, Italy, Poland
Mirati Therapeutics Inc.

Recruiting

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Colo-rectal Cancer

United States, Puerto Rico
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
HUYABIO International, LLC.

Recruiting

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Cancer | Colorectal Cancer | Lung Cancer | Solid Tumor | Non Small Cell Lung Cancer | Colon Cancer | Cancer of Pancreas

United States, Puerto Rico
Navire Pharma Inc., a BridgeBio company
Amgen

Recruiting

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (Argonaut)

Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Metastatic NSCLC

Spain, Australia, France, Denmark, Greece, Italy, Netherlands
Revolution Medicines, Inc.

Recruiting

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC) | Colorectal Cancer (CRC)

United States, Italy, Spain, Malaysia, Korea, Republic of, France, Australia, Thailand, Taiwan, Poland, Singapore, Czechia, Serbia

Search clinical trials for: Kras mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations